Pars Plana Vitrectomy Combined with Focal Endolaser Photocoagulation for Idiopathic Macular Telangiectasia

Overview

Journal Case Rep Med

Publisher Wiley

Specialty General Medicine

Date 2014 May 31

PMID 24876845

Citations 2

Authors

Gaku Terauchi

Celso Soiti Matsumoto

Kei Shinoda

Harue Matsumoto

Yutaka Imamura

Emiko Watanabe

Takaaki Kondo

Atsushi Mizota

Affiliations

Soon will be listed here.

Abstract

Background. To report the outcome of pars plana vitrectomy (PPV) combined with intraoperative endolaser focal photocoagulation (PC) on eyes with idiopathic macular telangiectasis (MacTel) type 1. Methods. This was a retrospective study of two female patients with MacTel type 1 who were resistant to focal photocoagulation, sub-Tenon triamcinolone injection, and/or antiangiogenic drugs. The best-corrected visual acuity (BCVA) was determined, and fluorescein angiography (FA) and spectral domain optical coherence tomography (SD-OCT) were performed before and after surgery for up to 19 months. Results. After surgery, the BCVA gradually improved from 20/100 to 20/20 at 19 months in Case 1 and from 20/50 to 20/13 at 13 months in Case 2. Fluorescein angiography (FA) showed leakage at the late phase, and OCT showed that the cystoid macular edema was resolved and the fovea was considerably thinner postoperatively. Conclusion. Patients with MacTel type 1 who are refractory to the other types of treatments can benefit from PPV combined with intraoperative endolaser focal PC with functional and morphological improvements.

Citing Articles

Comparison of anatomical and visual outcomes following different anti-vascular endothelial growth factor treatments in subretinal neovascular membrane secondary to type 2 proliferative macular telangiectasia.

Karasu B, Gunay B Graefes Arch Clin Exp Ophthalmol. 2019; 258(1):99-106.

PMID: 31768680 DOI: 10.1007/s00417-019-04520-x.

Widening use of dexamethasone implant for the treatment of macular edema.

Bonfiglio V, Reibaldi M, Fallico M, Russo A, Pizzo A, Fichera S Drug Des Devel Ther. 2017; 11:2359-2372.

PMID: 28860707 PMC: 5566324. DOI: 10.2147/DDDT.S138922.

References

Yannuzzi L, Bardal A, Freund K, Chen K, Eandi C, Blodi B . Idiopathic macular telangiectasia. Arch Ophthalmol. 2006; 124(4):450-60. DOI: 10.1001/archopht.124.4.450. View

Park D, Schatz H, McDonald H, Johnson R . Grid laser photocoagulation for macular edema in bilateral juxtafoveal telangiectasis. Ophthalmology. 1997; 104(11):1838-46. DOI: 10.1016/s0161-6420(97)30019-0. View

Li K, Goh T, Parsons H, Chan W, Lam D . Use of intravitreal triamcinolone acetonide injection in unilateral idiopathic juxtafoveal telangiectasis. Clin Exp Ophthalmol. 2005; 33(5):542-4. DOI: 10.1111/j.1442-9071.2005.01081.x. View

Ciarnella A, Verrilli S, Fenicia V, Mannino C, Cutini A, Perdicchi A . Intravitreal ranibizumab and laser photocoagulation in the management of idiopathic juxtafoveolar retinal telangiectasia type 1: a case report. Case Rep Ophthalmol. 2013; 3(3):298-303. PMC: 3530150. DOI: 10.1159/000342848. View

Sigler E, Randolph J, Calzada J, Charles S . Comparison of observation, intravitreal bevacizumab, or pars plana vitrectomy for non-proliferative type 2 idiopathic macular telangiectasia. Graefes Arch Clin Exp Ophthalmol. 2012; 251(4):1097-101. DOI: 10.1007/s00417-012-2150-1. View

Mandelcorn M, Nrusimhadevara R . Internal limiting membrane peeling for decompression of macular edema in retinal vein occlusion: a report of 14 cases. Retina. 2004; 24(3):348-55. DOI: 10.1097/00006982-200406000-00002. View

Gamulescu M, Walter A, Sachs H, Helbig H . Bevacizumab in the treatment of idiopathic macular telangiectasia. Graefes Arch Clin Exp Ophthalmol. 2008; 246(8):1189-93. DOI: 10.1007/s00417-008-0795-6. View

GASS J, Oyakawa R . Idiopathic juxtafoveolar retinal telangiectasis. Arch Ophthalmol. 1982; 100(5):769-80. DOI: 10.1001/archopht.1982.01030030773010. View

Martinez J . Intravitreal triamcinolone acetonide for bilateral acquired parafoveal telangiectasis. Arch Ophthalmol. 2003; 121(11):1658-9. DOI: 10.1001/archopht.121.11.1658. View

10.

Hirano Y, Yasukawa T, Usui Y, Nozaki M, Ogura Y . Indocyanine green angiography-guided laser photocoagulation combined with sub-Tenon's capsule injection of triamcinolone acetonide for idiopathic macular telangiectasia. Br J Ophthalmol. 2009; 94(5):600-5. DOI: 10.1136/bjo.2009.163790. View

11.

Chopdar A . Retinal telangiectasis in adults: fluorescein angiographic findings and treatment by argon laser. Br J Ophthalmol. 1978; 62(4):243-50. PMC: 1043196. DOI: 10.1136/bjo.62.4.243. View

12.

Mester U, Dillinger P . Vitrectomy with arteriovenous decompression and internal limiting membrane dissection in branch retinal vein occlusion. Retina. 2002; 22(6):740-6. DOI: 10.1097/00006982-200212000-00009. View

13.

Gandorfer A, Messmer E, Ulbig M, Kampik A . Resolution of diabetic macular edema after surgical removal of the posterior hyaloid and the inner limiting membrane. Retina. 2000; 20(2):126-33. View

14.

GASS J, Blodi B . Idiopathic juxtafoveolar retinal telangiectasis. Update of classification and follow-up study. Ophthalmology. 1993; 100(10):1536-46. View

15.

Moon B, Kim Y, Yoon Y, Lee J . Use of intravitreal bevacizumab injections to treat type 1 idiopathic macular telangiectasia. Graefes Arch Clin Exp Ophthalmol. 2011; 250(11):1697-9. DOI: 10.1007/s00417-011-1798-2. View